Stephen P. Jung

Statistics

Publications

Citations

297

H-Index

Active since

2003

Affiliations

PTC Therapeutics (United States)(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Rutgers, The State University of New Jersey

Harvard University

Stephen P. Jung is an author at PTC Therapeutics (United States) specializing in pharmacology, drug discovery, and antiviral structure-activity relationships.

ORCID

Publications per year

2003–2024

Publications

Inhibiting expression of specific genes in mammalian cells with 5′ end-mutated U1 small nuclear RNAs targeted to terminal exons of pre-mRNA

Puri Fortes, Yolanda Cuevas, Fei Guan et al. · Proceedings of the National Academy of Sciences · 2003 · 78 citations · Full text

Life Sciences, Genetics, Molecular Biology +15

Requirements for gene silencing mediated by U1 snRNA binding to a target sequence

Xabi Abad, María Vera, Stephen P. Jung et al. · Nucleic Acids Research · 2008 · 53 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

Structure–Activity Relationship (SAR) Optimization of 6-(Indol-2-yl)pyridine-3-sulfonamides: Identification of Potent, Selective, and Orally Bioavailable Small Molecules Targeting Hepatitis C (HCV) NS4B

Nanjing Zhang, Xiaoyan Zhang, Jin Zhu et al. · Journal of Medicinal Chemistry · 2013 · 43 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models

Grace Liu, Philip Lipari, Anna Mollin et al. · Human Molecular Genetics · 2023 · 20 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Identification of PTC725, an Orally Bioavailable Small Molecule That Selectively Targets the Hepatitis C Virus NS4B Protein

Zhengxian Gu, Jason D. Graci, Frederick Lahser et al. · Antimicrobial Agents and Chemotherapy · 2013 · 19 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

1–5 of 11